Tactogen is a Palo Alto-based public benefit corporation developing novel MDMA-like entactogens and psychedelic-adjacent molecules for psychiatric disorders. Founded in 2020 by neuroscientist Matthew Baggott and Luke Pustejovsky, Tactogen has built the largest known library of entactogenic compounds. Lead candidate TACT908 is a non-hallucinogenic 5-HT1B/2A agonist for cluster headache, while TACT833 targets alcohol use disorder and eating disorders. Following the 2024 FDA rejection of Lykos's MDMA, Tactogen has pivoted toward its novel NCE pipeline.
Drug Pipeline
3TACT908
Non-hallucinogenic 5-HT1B/2A agonist; positional isomer of DMT with indolizine ring. Preclinical for cluster headache.
TACT833
5-HT1B receptor modulator and monoamine transporter modulator. Targeting AUD and eating disorders.
TACT411
Novel entactogen; PTSD planned in Phase 1.
Quick Facts
- Type
- Public Benefit Corporation
- Founded
- 2020
- Lead Stage
- Pre-clinical
- Website
- Visit